EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Hannah Goulart iD, Hagop Kantarjian iD, Gautam Borthakur, Naval Daver iD, Courtney D DiNardo iD, Elias Jabbour iD, Naveen Pemmaraju iD, Yesid Alvarado, Himachandana Atluri, Musa Yilmaz, Fadi G Haddad iD, Kayleigh R Marx iD und 6 weitere

Cancer · 15.04.2025 · 131 (8)

DOI: 10.1002/cncr.35840 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 07.04.2025. Verfasst von Hannah Goulart und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Cytarabine, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Rama Guntupalli Endowment for Leukemia Research, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment of relapsed and/or refractory (R/R) acute myeloid leukemia (AML) remains challenging because of poor responses to chemotherapy. Efforts to improve outcomes have included the use of high‐dose cytarabine in combination with nucleoside analogs, such as cladribine. The authors evaluated combined cladribine, idarubicin, and cytarabine (CLIA) in a phase 2 trial of 66 patients with R/R AML.

Methods

Patients received induction with cladribine 5 mg/m 2 intravenously (days 1–5), cytarabine 1000 mg/m 2 intravenously (days 1–5), and idarubicin 10 mg/m 2 intravenously (days 1–3; CLIA). Sorafenib 400 mg twice daily (days 1–14) was added for FLT3 ‐mutated AML.

Results

The composite response rate (complete remission [CR] plus complete remission with incomplete hematologic recovery [CRi]) was 33%; salvage 1 (S1) patients ( n = 35) had a CR/CRi rate of 49%. After a 61‐month median follow‐up, the median overall survival (OS) was 7.9 months, with a median relapse‐free survival (RFS) of 9.1 months for those in CR/CRi. The median OS for S1 patients was 12 months, with a median RFS of 10.3 months. For those who received CLIA with sorafenib ( n = 22), the CR/CRi rate was 41%, median OS was 8.8 months, and median RFS was 3.8 months. Landmark analysis demonstrated superior OS for patients who proceeded to transplantation compared with patients who did not (median OS, 78 vs. 8.8 months, respectively; p < .001). The 4‐week and 8‐week mortality rates were 6% and 17%, respectively. Most grade >3 adverse events were related to infection and elevated liver function tests.

Conclusions

CLIA is effective for patients with R/R AML and offers a safety profile similar to that of other intensive regimens (ClinicalTrials.gov identifier NCT02115295).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytarabineLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansMaleFemaleIdarubicinMiddle AgedCladribineAdultAgedYoung AdultRemission InductionSorafenib

Stichwörter der Autor:innen

acute myeloid leukemia (AML)chemotherapycladribineclinical trial

Substanzen

CytarabineIdarubicinCladribineSorafenib

Autor:innen und Institutionen

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Hannah Goulart, Hagop Kantarjian, Naval Daver, Courtney D DiNardo, Elias Jabbour, Naveen Pemmaraju, Fadi G Haddad, Kayleigh R Marx, Caitlin Rausch, Guillermo Garcia-Manero, Tapan M Kadia

Förderung

  • NCI NIH HHS
  • Rama Guntupalli Endowment for Leukemia Research
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Goulart, H., Kantarjian, H., Borthakur, G., Daver, N., DiNardo, C. D., Jabbour, E., Pemmaraju, N., Alvarado, Y., Atluri, H., Yilmaz, M., Haddad, F. G., Marx, K. R., Rausch, C., Loghavi, S., Jain, N., Garcia-Manero, G., Ravandi-Kashani, F., & Kadia, T. M. (2025). Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial. Cancer, 131(8). https://doi.org/10.1002/cncr.35840

Vancouver

Goulart H, Kantarjian H, Borthakur G, Daver N, DiNardo CD, Jabbour E, et al. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial. Cancer. 2025;131(8). doi:10.1002/cncr.35840

BibTeX
@article{Goulart2025,
  author = {Goulart, Hannah and Kantarjian, Hagop and Borthakur, Gautam and Daver, Naval and DiNardo, Courtney D and Jabbour, Elias and Pemmaraju, Naveen and Alvarado, Yesid and Atluri, Himachandana and Yilmaz, Musa and Haddad, Fadi G and Marx, Kayleigh R and Rausch, Caitlin and Loghavi, Sanam and Jain, Nitin and Garcia-Manero, Guillermo and Ravandi-Kashani, Farhad and Kadia, Tapan M},
  title = {Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {8},
  doi = {10.1002/cncr.35840}
}
Kostenlos starten →